Ampliphi Biosciences Corp (APHB) 7.19 $APHB
Ear Infections - Global Clinical Trials Review 2015
M2 - Thu Sep 10, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8tvmpv/ear_infections) has announced the addition of the "Ear Infections Global Clinical Trials Review, H2, 2015" report to their offering. Ear Infections Global Clinical Trials Review, H2, 2015" provides an overview of Ear Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Ear Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Scope - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Top Companies Participating in Ear Infections Therapeutics Clinical Trials - Teva Pharmaceutical Industries Limited - GlaxoSmithKline Plc - MerLion Pharmaceuticals Pte Ltd - Merck & Co., Inc. - Laboratorios SALVAT S.A. - Highmark Inc. - Dr. Reddy's Laboratories Limited - Biocontrol Limited (Inactive) - Bfactory Health Products B.V. - AmpliPhi Biosciences Corporation Clinical Trial Overview of Top Institutes / Government - Babol University of Medical Sciences - Children's Oncology Group - Fremantle Hospital and Health Service - Guilan University of Medical Sciences - Maastricht University Medical Center - Medical Research Council - Medical University of Vienna - Nilratan Sircar Medical College - Texas Tech University Health Sciences Center - University of Oxford For more information visit http://www.researchandmarkets.com/research/8t...infections
MRK: 52.09 (-0.63), TEVA: 63.66 (+1.62), GSK: 40.26 (+0.02), APHB: 7.19 (+0.02)
AmpliPhi Biosciences to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Business Wire - Tue Sep 08, 7:05AM CDT
AmpliPhi Biosciences Corporation (NYSE: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that M. Scott Salka, CEO, will present a corporate overview on Thursday, September 10 at the Rodman & Renshaw 17th Annual Global Investment Conference taking place at the St. Regis Hotel in New York.
XON: 44.88 (+2.34), APHB: 7.19 (+0.02)
AmpliPhi Biosciences Announces Appointment of Alexander Gaidamaka as Vice President of Chemistry, Manufacturing and Control
Business Wire - Wed Sep 02, 3:15PM CDT
AmpliPhi Biosciences Corporation (NYSE: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that Alexander Gaidamaka, Ph.D., D.V.M, has been appointed as the new Vice President of Chemistry, Manufacturing and Control.
TST.TO: 0.43 (+0.02), XON: 44.88 (+2.34), APHB: 7.19 (+0.02)
AmpliPhi to Present at the 21st Biennial Evergreen International Phage Meeting
Business Wire - Wed Aug 05, 7:04AM CDT
AmpliPhi BioSciences Corporation (OTCQB:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that the Company will give a presentation today at the 21st Biennial Evergreen International Phage Meeting, taking place August 2-7 in Olympia, Wash.
XON: 44.88 (+2.34), APHB: 7.19 (+0.02)
AmpliPhi BioSciences Cleared to Submit Listing Application to NYSE MKT
Business Wire - Tue Aug 04, 7:05AM CDT
--Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on August 07, 2015
XON: 44.88 (+2.34), APHB: 7.19 (+0.02)
AmpliPhi to Present Research on Efficacy of a Novel Bacteriophage Cocktail in S. aureus Lung Infection Model at ICAAC/ICC 2015
Business Wire - Thu Jul 30, 3:10PM CDT
AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that data comparing the efficacy of its bacteriophage cocktail to vancomycin in a Staphylococcus aureus lung infection mouse model will be presented at the joint Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) 2015 meeting, September 17-21 in San Diego.
XON: 44.88 (+2.34), APHB: 7.19 (+0.02)
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Pipeline Report 2015 - 37 Companies & 57 Drug Profiles
M2 - Tue Jul 21, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vgmkjs/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Absynth Biologics Limited - Actelion Ltd - ActogeniX NV - Adenium Biotech ApS - AIMM Therapeutics B.V. - Akthelia pharmaceuticals ehf - AmpliPhi Biosciences Corporation - Assembly Biosciences, Inc. - AvidBiotics Corp. - C3 Jian, Inc - Daiichi Sankyo Company, Limited - Evec, Inc. - GangaGen Inc. - ImmunoBiology Ltd. - Immuron Limited - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Merck & Co., Inc. - MGB Biopharma Limited - Microbiotix, Inc. - Micropharm Ltd - Nanotherapeutics, Inc. - Novabiotics Ltd - Oragenics, Inc. - Pfizer Inc. - Procarta Biosystems Ltd - Prokarium Ltd. - Sanofi Pasteur SA - Sarum Biosciences Limited - Sequella, Inc. - Shire Plc - Sorrento Therapeutics, Inc. - Stellar Biotechnologies, Inc. - Summit Therapeutics plc. - Synthetic Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/vg...lostridium
PFE: 32.97 (+0.35), SRNE: 13.53 (+0.25), APHB: 7.19 (+0.02), INO: 7.34 (+0.23), SYN: 2.62 (+0.18), MRK: 52.09 (-0.63), SHPG: 223.00 (-2.43), ASMB: 13.98 (+0.01), OGEN: 2.55 (unch)
Acinetobacter Infections Therapeutics Pipeline Review, H1 2015 - 25 Companies & 43 Drug Profiles
M2 - Thu Jul 09, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w32xnp/acinetobacter) has announced the addition of the "Acinetobacter Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - AmpliPhi Biosciences Corporation - Aridis Pharmaceuticals LLC - AstraZeneca PLC - AvidBiotics Corp. - ConjuGon, Inc. - Emergent BioSolutions Inc. - FAB Pharma - LegoChem Biosciences, Inc - Melinta Therapeutics, Inc - Microbiotix, Inc. - Northern Antibiotics Oy - Nosopharm SAS - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Phylogica Limited - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Shionogi & Co., Ltd. - Synthetic Biologics, Inc. - Techulon, Inc. - Trana Discovery, Inc. - Vaxdyn, S.L. For more information visit http://www.researchandmarkets.com/research/w3...netobacter
SYN: 2.62 (+0.18), EBS: 32.58 (+0.39), SRPT: 35.94 (+1.49), PFE: 32.97 (+0.35), AZN: 33.30 (+0.02), AKAO: 6.80 (+0.28), APHB: 7.19 (+0.02)
AmpliPhi Announces New Data Demonstrating Anti-Pseudomonal Bacteriophages Retained Biological Activity Following Nebulization
Business Wire - Fri Jun 12, 7:00AM CDT
AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced new data demonstrating that bacteriophages remain active against Pseudomonas aeruginosa (P. aeruginosa) after nebulization. Data from this study, performed in collaboration with the Royal Brompton Hospital and Imperial College, UK, were presented at the 38th European Cystic Fibrosis Conference, taking place in Brussels, Belgium from June 10-13.
XON: 44.88 (+2.34), APHB: 7.19 (+0.02)
AmpliPhi Biosciences Corporation - Product Pipeline Review - 2014
M2 - Mon Jun 08, 7:23AM CDT
Product Pipeline Review - 2014
APHB: 7.19 (+0.02)
AmpliPhi to Present New Data on Biological Activity of Nebulized Anti-Pseudomonal Bacteriophage
Business Wire - Mon Jun 08, 7:03AM CDT
AmpliPhi BioSciences Corporation (OTCQB:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that new data on the activity of P. aeruginosa bacteriophages after exposure to nebulizer systems applicable for use in future clinical trials will be presented at the European Cystic Fibrosis Conference, taking place in Brussels, Belgium from June 10-13.
XON: 44.88 (+2.34), APHB: 7.19 (+0.02)
Global Leber Congenital Amaurosis (LCA) Therapeutics Pipeline Review, H1 2015 - 6 Companies & 7 Drug Profiles
M2 - Fri Jun 05, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zgpfl2/leber_congenital) has announced the addition of the "Leber Congenital Amaurosis (LCA) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Leber Congenital Amaurosis (LCA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leber Congenital Amaurosis (LCA) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AmpliPhi Biosciences Corporation - Applied Genetic Technologies Corporation - BBB Therapeutics B.V. - ProQR Therapeutics N.V. - QLT Inc. - Spark Therapeutics, Inc. Drug Profiles - Gene Therapy to Activate Retinal Guanylyl Cyclase-1 for Leber Congenital Amaurosis-1 - QLT-091001 - QR-110 - rAAV2-CB-hRPE65 - Small Molecules for Inherited Retinal Diseases - SPK-RPE-65 - tgAAG-76 For more information visit http://www.researchandmarkets.com/research/zg...congenital
QLTI: 3.44 (unch), ONCE: 46.06 (+2.03), APHB: 7.19 (+0.02)
AmpliPhi's manufacturing facility awarded cGMP certification to manufacture bacteriophage products for human use
M2 - Thu Jun 04, 3:44AM CDT
Antibacterial therapy company AmpliPhi BioSciences (OtherOTC:APHB) stated on Wednesday that its production facility in Ljubljana, Slovenia has passed the JAZMP's
Ear Infections - Global Clinical Trials Review 2015
M2 - Thu Sep 10, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8tvmpv/ear_infections) has announced the addition of the "Ear Infections Global Clinical Trials Review, H2, 2015" report to their offering. Ear Infections Global Clinical Trials Review, H2, 2015" provides an overview of Ear Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Ear Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Scope - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Top Companies Participating in Ear Infections Therapeutics Clinical Trials - Teva Pharmaceutical Industries Limited - GlaxoSmithKline Plc - MerLion Pharmaceuticals Pte Ltd - Merck & Co., Inc. - Laboratorios SALVAT S.A. - Highmark Inc. - Dr. Reddy's Laboratories Limited - Biocontrol Limited (Inactive) - Bfactory Health Products B.V. - AmpliPhi Biosciences Corporation Clinical Trial Overview of Top Institutes / Government - Babol University of Medical Sciences - Children's Oncology Group - Fremantle Hospital and Health Service - Guilan University of Medical Sciences - Maastricht University Medical Center - Medical Research Council - Medical University of Vienna - Nilratan Sircar Medical College - Texas Tech University Health Sciences Center - University of Oxford For more information visit http://www.researchandmarkets.com/research/8t...infections
MRK: 52.09 (-0.63), TEVA: 63.66 (+1.62), GSK: 40.26 (+0.02), APHB: 7.19 (+0.02)
AmpliPhi Biosciences to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Business Wire - Tue Sep 08, 7:05AM CDT
AmpliPhi Biosciences Corporation (NYSE: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that M. Scott Salka, CEO, will present a corporate overview on Thursday, September 10 at the Rodman & Renshaw 17th Annual Global Investment Conference taking place at the St. Regis Hotel in New York.
XON: 44.88 (+2.34), APHB: 7.19 (+0.02)
AmpliPhi Biosciences Announces Appointment of Alexander Gaidamaka as Vice President of Chemistry, Manufacturing and Control
Business Wire - Wed Sep 02, 3:15PM CDT
AmpliPhi Biosciences Corporation (NYSE: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that Alexander Gaidamaka, Ph.D., D.V.M, has been appointed as the new Vice President of Chemistry, Manufacturing and Control.
TST.TO: 0.43 (+0.02), XON: 44.88 (+2.34), APHB: 7.19 (+0.02)
AmpliPhi to Present at the 21st Biennial Evergreen International Phage Meeting
Business Wire - Wed Aug 05, 7:04AM CDT
AmpliPhi BioSciences Corporation (OTCQB:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that the Company will give a presentation today at the 21st Biennial Evergreen International Phage Meeting, taking place August 2-7 in Olympia, Wash.
XON: 44.88 (+2.34), APHB: 7.19 (+0.02)
AmpliPhi BioSciences Cleared to Submit Listing Application to NYSE MKT
Business Wire - Tue Aug 04, 7:05AM CDT
--Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on August 07, 2015
XON: 44.88 (+2.34), APHB: 7.19 (+0.02)
AmpliPhi to Present Research on Efficacy of a Novel Bacteriophage Cocktail in S. aureus Lung Infection Model at ICAAC/ICC 2015
Business Wire - Thu Jul 30, 3:10PM CDT
AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that data comparing the efficacy of its bacteriophage cocktail to vancomycin in a Staphylococcus aureus lung infection mouse model will be presented at the joint Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) 2015 meeting, September 17-21 in San Diego.
XON: 44.88 (+2.34), APHB: 7.19 (+0.02)
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Pipeline Report 2015 - 37 Companies & 57 Drug Profiles
M2 - Tue Jul 21, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vgmkjs/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Absynth Biologics Limited - Actelion Ltd - ActogeniX NV - Adenium Biotech ApS - AIMM Therapeutics B.V. - Akthelia pharmaceuticals ehf - AmpliPhi Biosciences Corporation - Assembly Biosciences, Inc. - AvidBiotics Corp. - C3 Jian, Inc - Daiichi Sankyo Company, Limited - Evec, Inc. - GangaGen Inc. - ImmunoBiology Ltd. - Immuron Limited - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Merck & Co., Inc. - MGB Biopharma Limited - Microbiotix, Inc. - Micropharm Ltd - Nanotherapeutics, Inc. - Novabiotics Ltd - Oragenics, Inc. - Pfizer Inc. - Procarta Biosystems Ltd - Prokarium Ltd. - Sanofi Pasteur SA - Sarum Biosciences Limited - Sequella, Inc. - Shire Plc - Sorrento Therapeutics, Inc. - Stellar Biotechnologies, Inc. - Summit Therapeutics plc. - Synthetic Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/vg...lostridium
PFE: 32.97 (+0.35), SRNE: 13.53 (+0.25), APHB: 7.19 (+0.02), INO: 7.34 (+0.23), SYN: 2.62 (+0.18), MRK: 52.09 (-0.63), SHPG: 223.00 (-2.43), ASMB: 13.98 (+0.01), OGEN: 2.55 (unch)
Acinetobacter Infections Therapeutics Pipeline Review, H1 2015 - 25 Companies & 43 Drug Profiles
M2 - Thu Jul 09, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w32xnp/acinetobacter) has announced the addition of the "Acinetobacter Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - AmpliPhi Biosciences Corporation - Aridis Pharmaceuticals LLC - AstraZeneca PLC - AvidBiotics Corp. - ConjuGon, Inc. - Emergent BioSolutions Inc. - FAB Pharma - LegoChem Biosciences, Inc - Melinta Therapeutics, Inc - Microbiotix, Inc. - Northern Antibiotics Oy - Nosopharm SAS - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Phylogica Limited - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Shionogi & Co., Ltd. - Synthetic Biologics, Inc. - Techulon, Inc. - Trana Discovery, Inc. - Vaxdyn, S.L. For more information visit http://www.researchandmarkets.com/research/w3...netobacter
SYN: 2.62 (+0.18), EBS: 32.58 (+0.39), SRPT: 35.94 (+1.49), PFE: 32.97 (+0.35), AZN: 33.30 (+0.02), AKAO: 6.80 (+0.28), APHB: 7.19 (+0.02)
AmpliPhi Announces New Data Demonstrating Anti-Pseudomonal Bacteriophages Retained Biological Activity Following Nebulization
Business Wire - Fri Jun 12, 7:00AM CDT
AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced new data demonstrating that bacteriophages remain active against Pseudomonas aeruginosa (P. aeruginosa) after nebulization. Data from this study, performed in collaboration with the Royal Brompton Hospital and Imperial College, UK, were presented at the 38th European Cystic Fibrosis Conference, taking place in Brussels, Belgium from June 10-13.
XON: 44.88 (+2.34), APHB: 7.19 (+0.02)
AmpliPhi Biosciences Corporation - Product Pipeline Review - 2014
M2 - Mon Jun 08, 7:23AM CDT
Product Pipeline Review - 2014
APHB: 7.19 (+0.02)
AmpliPhi to Present New Data on Biological Activity of Nebulized Anti-Pseudomonal Bacteriophage
Business Wire - Mon Jun 08, 7:03AM CDT
AmpliPhi BioSciences Corporation (OTCQB:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that new data on the activity of P. aeruginosa bacteriophages after exposure to nebulizer systems applicable for use in future clinical trials will be presented at the European Cystic Fibrosis Conference, taking place in Brussels, Belgium from June 10-13.
XON: 44.88 (+2.34), APHB: 7.19 (+0.02)
Global Leber Congenital Amaurosis (LCA) Therapeutics Pipeline Review, H1 2015 - 6 Companies & 7 Drug Profiles
M2 - Fri Jun 05, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zgpfl2/leber_congenital) has announced the addition of the "Leber Congenital Amaurosis (LCA) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Leber Congenital Amaurosis (LCA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leber Congenital Amaurosis (LCA) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AmpliPhi Biosciences Corporation - Applied Genetic Technologies Corporation - BBB Therapeutics B.V. - ProQR Therapeutics N.V. - QLT Inc. - Spark Therapeutics, Inc. Drug Profiles - Gene Therapy to Activate Retinal Guanylyl Cyclase-1 for Leber Congenital Amaurosis-1 - QLT-091001 - QR-110 - rAAV2-CB-hRPE65 - Small Molecules for Inherited Retinal Diseases - SPK-RPE-65 - tgAAG-76 For more information visit http://www.researchandmarkets.com/research/zg...congenital
QLTI: 3.44 (unch), ONCE: 46.06 (+2.03), APHB: 7.19 (+0.02)
AmpliPhi's manufacturing facility awarded cGMP certification to manufacture bacteriophage products for human use
M2 - Thu Jun 04, 3:44AM CDT
Antibacterial therapy company AmpliPhi BioSciences (OtherOTC:APHB) stated on Wednesday that its production facility in Ljubljana, Slovenia has passed the JAZMP's
